BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.
BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tisle...more >
|Stock Quote||more >|
11/16/18 4:00 p.m. ET
Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.
|Recent Press Releases||more >|
|BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology - November 16, 2018|
|CAMBRIDGE, Mass., and BEIJING, China, Nov. 16, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a c... Read More|
|Priority Review Granted to BeiGene’s New Drug Applications for Zanubrutinib and Tislelizumab in China - November 15, 2018|
|CAMBRIDGE, Mass., and BEIJING, China, Nov. 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a c... Read More|